24 May 2022
Latham & Watkins Represents ApiJect in US$111 Million Equity Investment by Royalty Pharma and Jefferies
Advising firms
Deal team
10 lawyers named| Lawyer | Firm | Seniority | Practice | Office |
|---|---|---|---|---|
| Nathan Ajiashvili Lead | Latham & Watkins LLP | Partner | corporate | New York |
| Daniel Hoffman | Latham & Watkins LLP | Partner | corporate | Boston |
| Jana Kovich | Latham & Watkins LLP | Associate | corporate | Chicago |
| Kristine LaVeau | Latham & Watkins LLP | Associate | corporate | Chicago |
| Autumn Schmidt | Latham & Watkins LLP | Associate | corporate | Chicago |
| David Della Rocca | Latham & Watkins LLP | Partner | benefits & compensation | Washington, D.C. |
| Victoria Wolfe | Latham & Watkins LLP | Associate | benefits & compensation | Chicago |
| Eric Kamerman | Latham & Watkins LLP | Partner | tax | New York |
| Joseph Simei | Latham & Watkins LLP | Counsel | antitrust | Washington, D.C. |
| Jim Barker | Latham & Watkins LLP | Partner | CFIUS | Washington, D.C. |
Stated terms
- Stated value
- USD 111m (US$111 million)
- What the figure measures
- Total transaction value
- Client
- ApiJect Holdings, Inc.Issuer
- Counterparties
- Royalty Pharma (Investor)
Jefferies Financial Group (Investor)